Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating IGNX001 for peanut allergy, focusing on safety, tolerability, pharmacokinetics and pharmacodyna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• IGNX001

Snippet

Sponsor: IgGenix Australia Pty Ltd | Conditions: Peanut Allergy | Phase 1 | Status: COMPLETED